Parley News & Learning

The latest on our clinical trial, our research, and the science of central hearing loss.

All Posts
Company News
External Coverage
Learning

Spotlight by CU Innovations

October 2025 — CU Innovations profiles the Klug Lab's path from basic research on the auditory brainstem to a clinical-stage spinout, highlighting the SPARK Award and the road ahead for LOOT therapy

February 4, 2026
Read more

Celebrating Innovation: Dr. Benzheng Li's Emerging Research Grant Extended for Year Two

September 2025 — The Hearing Health Foundation extends Dr. Benzheng Li's Emerging Research Grant for a second year, supporting continued investigation into the auditory brainstem mechanisms underlying central hearing loss.

September 1, 2025
Read more

NIH Awards Multi-PI R01 to Study Mechanisms of Central Hearing Loss

August 2025 — A new multi-PI R01 from the NIH funds deeper investigation into the demyelination process driving age-related cocktail party syndrome — strengthening the basic science foundation behind LOOT.

August 10, 2025
Read more

Spotlight by CU Innovations

October 2025 — CU Innovations profiles the Klug Lab's path from basic research on the auditory brainstem to a clinical-stage spinout, highlighting the SPARK Award and the road ahead for LOOT therapy

February 4, 2026
Read more

Celebrating Innovation: Dr. Benzheng Li's Emerging Research Grant Extended for Year Two

September 2025 — The Hearing Health Foundation extends Dr. Benzheng Li's Emerging Research Grant for a second year, supporting continued investigation into the auditory brainstem mechanisms underlying central hearing loss.

September 1, 2025
Read more

NIH Awards Multi-PI R01 to Study Mechanisms of Central Hearing Loss

August 2025 — A new multi-PI R01 from the NIH funds deeper investigation into the demyelination process driving age-related cocktail party syndrome — strengthening the basic science foundation behind LOOT.

August 10, 2025
Read more
No items found.
The ScienceFor CliniciansAboutNewsContactPrivacy PolicyTerms and Conditions

Parley Neurotech's experimental therapy has not yet been reviewed by the FDA. It will soon be accessible in Montana under the soon to be implemented right to try law, state Senate Bill 5353. Informed and consenting adults may request this experimental treatment in Montana from their clinician prior to FDA review of efficacy claims. Safety of the small molecule component of Parley Neurotech's combination therapy, clemastine fumarate at a lower dosage, has been approved by the FDA since 1977.